Story

ResMed Stock Slides After Tepid Guidance Overshadows EPS Beat

ENTHMSVIIDZHZH-TWJAKOHI
Aug 7, 20261 min read
ResMed Stock Slides After Tepid Guidance Overshadows EPS Beat
Text size
Background

ResMed (RMD) shares fell sharply in pre-market trading Friday after the sleep and respiratory care device maker issued a cautious growth forecast that overshadowed a fourth-quarter earnings beat. The company's inaugural full-year guidance signaled a significant slowdown, disappointing investors and triggering a series of analyst price target cuts.

Mixed Results and Weak Forecast

For its fiscal fourth quarter, ResMed reported a non-GAAP earnings per share of $2.95, a 16% year-over-year increase that narrowly beat the consensus estimate of approximately $2.89. However, quarterly revenue of $1.46 billion fell just shy of Wall Street's expectation for $1.47 billion.

The more significant concern for investors was the company's first-ever full-year guidance. ResMed projected core revenue growth of just 5% to 7% for fiscal 2027, a marked deceleration from the 8% constant-currency growth it achieved in fiscal 2026. This outlook includes an anticipated $75 million revenue headwind related to a field safety action on its Astral ventilator line.

Compounding Headwinds

Sample IUX Markets – In-articleAd

Adding to the pressure on future earnings, ResMed noted two other factors expected to be dilutive to EPS in the upcoming year. These include the pending divestiture of its MatrixCare software business and the recently closed $340 million acquisition of Noctrix Health.

The combination of the revenue miss and the weaker-than-expected outlook prompted several Wall Street analysts, including those at RBC Capital and Wells Fargo, to trim their price targets on the stock. The pre-market decline of 5.5% was entirely company-specific, as the broader S&P 500 was trading flat.

Market Impact

The sell-off pushed ResMed shares, which closed the prior session at $223.24, toward the lower end of their 52-week range of $180.26 to $293.81. The negative investor reaction underscores the market's focus on forward-looking growth, with the cautious guidance outweighing the modest earnings outperformance in the most recent quarter.

Read next

More on Stocks
Back to latest news

LATEST